## Samchundang Pharm, Shaken Trust… The Dilemma of 'Unconfirmed' Disclosures and R&D Reduction
### [Background]
Samchundang Pharm is a pharmaceutical and bio company that has grown mainly by developing ophthalmic disease treatments. In particular, expectations for the development of an oral macular degeneration treatment have driven up the stock price and attracted investors' attention. However, the recent controversy over 23 'unconfirmed' disclosures has raised questions about the company's transparency. 'Unconfirmed' disclosures refer to disclosing important corporate decisions or contract details in an unconfirmed state, which causes confusion for investors and acts as a factor amplifying uncertainty. In the past, some bio companies have lost market trust by repeatedly issuing 'unconfirmed' disclosures due to delays in clinical trial results announcements and termination of technology transfer agreements. In this situation, Samchundang Pharm's 'unconfirmed' disclosure controversy is instilling anxiety in investors and raising concerns that it could lead to a decline in corporate value.
### [Current Situation]
As of local time on April 3, 2026, Samchundang Pharm is embroiled in a controversy over 23 'unconfirmed' disclosures, and the situation is further deteriorating with the additional announcement of a decision to reduce research and development (R&D) investment. Although the specific scale of the R&D investment reduction has not yet been disclosed, the market generally expects that this decision will negatively affect Samchundang Pharm's core competitiveness in new drug development. In particular, the uncertainty surrounding the development of an oral macular degeneration treatment is maximizing investors' anxiety. An anonymous securities analyst said, "The unusually large number of 'unconfirmed' disclosures by Samchundang Pharm suggests that there is a serious problem with the company's information management system," and analyzed, "The decision to reduce R&D investment could lead to a weakening of long-term growth engines and further fuel the deterioration of investment sentiment." Currently, Samchundang Pharm is under investigation by financial authorities in connection with the 'unconfirmed' disclosure controversy and faces the risk of being reported. The company stated that "there are parts that are different from the facts and will actively explain," but market concerns are not easily subsiding.
### [Multi-faceted Analysis]
Samchundang Pharm's 'unconfirmed' disclosure controversy and R&D investment reduction are not just a problem for one company, but could have a serious impact on the domestic bio industry as a whole. First, it can cause a contraction in investment sentiment, which can deepen the difficulty of raising funds for bio companies. In particular, small and medium-sized bio companies with technological capabilities but insufficient capital may face a threat to their survival. In addition, the Samchundang Pharm situation is expected to further strengthen the demand for transparency in the information disclosure of bio companies. Financial authorities are likely to strengthen regulations to prevent the indiscriminate issuance of 'unconfirmed' disclosures, and investors will demand a thorough review of the company's disclosure content. Furthermore, there are concerns that this situation could lead to a weakening of the competitiveness of the domestic bio industry. R&D investment is the core engine of new drug development and technological innovation, but investment reduction can undermine the long-term growth potential of the bio industry. Experts point out that domestic bio companies should take the Samchundang Pharm situation as an opportunity to enhance transparency and strengthen efforts to improve R&D investment efficiency. In addition, the government should pursue regulatory easing and investment promotion policies in parallel for the healthy development of the bio industry.
### [Future Prospects]
In the future, Samchundang Pharm's stock price is expected to fluctuate significantly depending on whether the 'unconfirmed' disclosure controversy is resolved and changes in R&D investment plans. If Samchundang Pharm receives unfavorable results from the financial authorities' investigation or expands the scale of R&D investment reduction, a stock price decline will be inevitable. On the other hand, if it successfully resolves the 'unconfirmed' disclosure controversy and succeeds in improving R&D investment efficiency, it can seize the opportunity for a stock price rebound. Investors should carefully examine Samchundang Pharm's disclosure content and management's statements and make investment decisions carefully. In particular, it is necessary to thoroughly analyze the specific content and resolution process of 'unconfirmed' disclosures and continuously check whether R&D investment plans have been changed. In addition, it is a good idea to continuously monitor news and analysis articles related to Samchundang Pharm and refer to the advice of investment experts. It is important to keep in mind that the Samchundang Pharm situation can have a significant impact on the investment environment of the domestic bio industry, and it is important to diversify the investment portfolio to spread the risk. AI believes that Samchundang Pharm's crisis is likely to lead not only to a short-term adjustment but also to a decline in the credibility of the bio industry as a whole and a contraction in investment sentiment. In particular, in a situation where concerns about interest rate hikes and economic recession continue, the difficulty of raising funds for bio companies is expected to deepen further. Investors will have to be more careful in distinguishing the good from the bad.
